HC Wainwright & Co. Reiterates Buy on Metagenomi, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Metagenomi (NASDAQ:MGX) and maintained a price target of $7, indicating continued confidence in the company's potential.
October 15, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Metagenomi and maintained a $7 price target, suggesting confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. indicates a positive outlook for Metagenomi. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100